FOR IMMEDIATE RELEASE
November 12, 2025
MEDIA CONTACT
Kaitlyn Francis, kaitlyn@rebuttalpr.com
GIRARD SHARP SECURES FINAL APPROVAL OF $195 MILLION XYREM ANTITRUST SETTLEMENT
Settlement resolves litigation against Jazz Pharmaceuticals, Hikma Pharmaceuticals
SAN FRANCISCO, CA – Girard Sharp LLP, a national leader in class action and antitrust litigation, is pleased to announce that the United States District Court for the Northern District of California has granted final approval for two settlements resolving the Xyrem antitrust litigation. The settlements, totaling $195 million, resolve claims against Jazz Pharmaceuticals and Hikma Pharmaceuticals for their alleged anticompetitive conduct related to the sale of Xyrem, a drug used to treat narcolepsy.
In granting final approval, the Court recognized the significance of the settlements, which provide substantial relief to union health plans, businesses, and other entities that paid for Xyrem prescriptions, noting that the $195 million recovery represents a 46% recovery on the estimated damages. This recovery is among the largest in recent years for end-payor class actions involving generic drug delays.
“An excellent job was done in this case,” said The Honorable Richard Seeborg, Chief Judge of the United States District Court for the Northern District of California, in his order. “And I congratulate you and congratulate the defense side on reaching your resolution and litigating it very effectively.”
“These settlements bring closure to a complex, multi-year battle and provide much-needed financial relief to the impacted class members,” said Dena Sharp, Managing Partner at Girard Sharp. “This case underscores our commitment to holding pharmaceutical companies accountable for practices that delay competition and keep prices for prescription drugs higher than they should be.”
The case, filed in 2020, focused on the defendants’ alleged efforts to delay the entry of a generic version of Xyrem, thereby maintaining supracompetitive prices shouldered by the class of payers for these important prescription drugs. More information on the settlements can be found at inrexyremantitrustlitigation.com.
##
Girard Sharp is a law firm headquartered in San Francisco, California that has established a record of successful outcomes in class and collective actions, multidistrict litigation, arbitrations, and other complex litigation in federal and state courts across the country. Our clients range from individual consumers and small businesses to Fortune 100 corporations and public retirement systems. Our team of experienced attorneysrepresents plaintiffs in a diverse set of fields, including antitrust, securities and financial fraud, product defects, digital privacy and data security, sexual abuse and women’s advocacy, consumer protection, and whistleblower laws.